An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study is testing a new medication called Luspatercept. It's for people in the UK who have a blood condition called myelofibrosis, which causes anaemia (low red blood cells), and who need regular blood transfusions. Participants must already be taking a JAK2 inhibitor medicine for their myelofibrosis. The main goal is to find out if Luspatercept is safe and effective at reducing how often people need blood transfusions. Some people will receive Luspatercept, while others will get a placebo (a dummy drug). This helps doctors understand if the new drug truly works. Participants will be carefully monitored throughout the study.
En un coup d'œil
Résultats
Résultats de cette étude
Publié July 2026Les résultats de cette étude ont été publiés.
De quoi parle cette étude ?
This research study is about a condition called myelofibrosis. Myelofibrosis is a rare type of blood cancer where the bone marrow, which makes blood cells, becomes scarred and doesn't work properly. This often leads to severe anaemia, meaning your body doesn't have enough red blood cells to carry oxygen, making you feel tired and weak. Many people with myelofibrosis need regular blood transfusions.
Doctors are testing a new drug called Luspatercept (you might also see it called ACE-536). It's designed to help your body make more healthy red blood cells. The study wants to see if Luspatercept can help people with myelofibrosis reduce the number of blood transfusions they need, and if it's generally safe to use. You would be eligible if you're already taking a specific type of medication called a JAK2 inhibitor for your myelofibrosis.
In this study, some people will receive Luspatercept, and others will get a placebo, which looks like the study drug but contains no active medicine. This is a common way to test new drugs reliably. At first, neither you nor your doctor will know if you're getting the active drug or the placebo. After about six months, if you haven't seen a benefit, you'll have the option to find out what you were taking. If you were on the placebo, you might then be able to start taking Luspatercept.
Points clés
- This study tests a new drug, Luspatercept, for myelofibrosis with anaemia.
- It aims to reduce the need for blood transfusions.
- Participants must already be taking a JAK2 inhibitor.
- Some will receive the drug, others a placebo (dummy drug).
- Close medical monitoring will be provided throughout.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of myelofibrosis. Critically, you must be experiencing anaemia that requires regular red blood cell transfusions. This means you’ve had between 4 and 12 red blood cell units over the last 12 weeks, and you haven’t gone longer than six weeks without a transfusion.
You must also already be taking a JAK2 inhibitor medication for your myelofibrosis. This medication needs to have been stable (same dose, no interruptions) for a certain period before the study starts. Your general health should also be reasonably good, as assessed by a doctor, meaning you're able to carry out most daily activities.
There are also some types of other medications or therapies that you cannot be taking while in this study, such as certain cancer drugs (other than your JAK2 inhibitor), specific blood cell growth factors, or certain older medications for blood conditions. Your study doctor will review all your current medications carefully to make sure you can safely participate.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Do you have myelofibrosis and need regular blood transfusions (at least 4 units in the last 12 weeks)?
- Are you currently taking a JAK2 inhibitor medication for your myelofibrosis?
- Has your JAK2 inhibitor dose been stable for at least 16 weeks?
- Are you generally well enough to do most daily activities?
En quoi consiste la participation ?
If you decide to take part, the study will involve several stages. First, there's a 'screening period' where doctors will check if you meet all the requirements. If you do, you'll enter the 'treatment phase'. This phase starts with a period where you'll receive either Luspatercept or a placebo, and neither you nor your doctors will know which one. This part lasts for around six months. During this time, you will continue your usual JAK2 inhibitor treatment and other supportive care, like blood transfusions if needed.
Around day 169 (about 5.5 months), your response to the treatment will be checked. If you haven't shown improvement, you'll have the option to find out if you were on the active drug or placebo. If you were on the placebo, you might then be able to receive Luspatercept. The study involves regular clinic visits for assessments, blood tests, and to get your study medication. You'll then have a follow-up period after your treatment ends. The total duration of your involvement could be quite long, potentially over a year, depending on which treatment arm you are in and if you continue into the extension periods.
Risques et avantages potentiels
Locations (185)
- Local Institution - 110Code postal vérifiéLos Angeles, États-Unis
- Local Institution - 135Code postal vérifiéOrlando, United States
- Local Institution - 133Code postal vérifiéPlantation, United States
- Local Institution - 112Code postal vérifiéChicago, États-Unis
- Local Institution - 124Code postal vérifiéLexington, United States
- Local Institution - 114Code postal vérifiéAnn Arbor, États-Unis
- Local Institution - 108Code postal vérifiéSaint Louis, États-Unis
- John Theurer Cancer CenterCode postal vérifiéHackensack, United States
- Mount Sinai Medical CenterCode postal vérifiéNew York, États-Unis
- University of Pittsburg Medical CenterCode postal vérifiéPittsburgh, United States
- Allegheny Health NetworkCode postal vérifiéPittsburgh, United States
- Local Institution - 130Code postal vérifiéKnoxville, United States
Questions fréquentes
What is myelofibrosis?
It's a rare blood cancer where your bone marrow becomes scarred, affecting its ability to make healthy blood cells, often leading to anaemia.
What is Luspatercept?
It's a new medication being tested to help your body produce more red blood cells, potentially reducing the need for blood transfusions.
Qu'est-ce qu'un placebo ?
A placebo is a 'dummy' treatment that looks like the study drug but contains no active medicine. It helps compare the new drug's effects.
Will I still take my JAK2 inhibitor?
Yes, you must continue your stable JAK2 inhibitor treatment throughout the study as part of your standard care.
Puis-je quitter l'étude à tout moment ?
Yes, you are free to withdraw from the study for any reason at any point, without it affecting your medical care.
Comment en savoir plus
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.